A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
Saye Khoo(University of Liverpool), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Lara Lavelle-Langham(University of Liverpool), Sean Ewings(Cancer Research UK), Shazaad Ahmad(Manchester University NHS Foundation Trust), Julian A. Hiscox(University of Liverpool), Amanda Buadi(University Hospital Southampton NHS Foundation Trust), William Greenhalf(University of Liverpool), Wayne Holman, David Cameron(Lancashire Teaching Hospitals NHS Foundation Trust), Richard J. Fitzgerald(University of Limerick), Thomas Jaki(MRC Biostatistics Unit), Victoria Shaw(University of Liverpool), Thomas Edwards(Liverpool School of Tropical Medicine), I’ah Donovan-Banfield(University of Liverpool), Helen Reynolds(University of Liverpool), David G. Lalloo(Liverpool School of Tropical Medicine), Michael Jacobs(Roland Hill (United Kingdom)), Emma Knox(University of Southampton), Pavel Mozgunov(University of Cambridge), Wendy Painter, Jimstan Periselneris(King's College Hospital NHS Foundation Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Lauren Walker(University of Liverpool), Katie Bullock(University of Liverpool), Christie Woods(Royal Liverpool and Broadgreen University Hospital NHS Trust), Michelle Tetlow(University of Liverpool), Colin Hale(Royal Liverpool and Broadgreen University Hospital NHS Trust), Rebecca Lyon(Royal Liverpool and Broadgreen University Hospital NHS Trust), Geoffrey Saunders(University of Southampton), Justin Chiong(University of Liverpool), Dennis Hadjiyiannakis(Lancashire Teaching Hospitals NHS Foundation Trust), Calley Middleton(University of Southampton), Nichola Downs(University Hospital Southampton NHS Foundation Trust)
Cited by 3
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k